ArticleThoracic cancer2022
Dynamic
Article in Thoracic cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 3 syntheses or guidelines pooled it, 21 citations in OpenAlex.
- 18F-FDG PET/CT for predicting major pathological response to neoadjuvant therapy in non-small cell lung cancer: a meta-analysis.Frontiers in oncology · 2026Pooled it
- Diagnostic performance of 18F-FDG PET/CT metabolic parameters for early prediction of pathological response in NSCLC treated with neoadjuvant immuno(chemo)therapy: A systematic review and meta-analysis.European journal of nuclear medicine and molecular imaging · 2026Pooled it
- Comparative Efficacy and Safety of Neoadjuvant Immunotherapy with Nivolumab vs. Pembrolizumab in Resectable Non-Small Cell Lung Cancer: A Systematic Review.Current oncology (Toronto, Ont.) · 2024Pooled it
- Molecular imaging usingAnnals of nuclear medicine · 2025Trial
- Clinical predictors of pathological response after immunotherapy in salvage surgery for non-small cell lung cancer: a supplementary analysis of the CReGYT-05 immune checkpoint inhibitor-salvage study.General thoracic and cardiovascular surgery · 2026Article
- Pseudoprogression in neoadjuvant immunotherapy for resectable NSCLC: a PET-CT-based study.ESMO open · 2026Article
- Predictive Value of Circulating Tumor Cells in Neoadjuvant Chemoimmunotherapy for Non-Small Cell Lung Cancer.Thoracic cancer · 2026Article
- The value of positron emission tomography scan in predicting pathologic response of non-small cell lung cancer managed by neoadjuvant chemo-immunotherapy.Journal of thoracic disease · 2026Article
- Predictive modeling of immunotherapy efficacy in driver gene-negative non-small cell lung cancer.Translational lung cancer research · 2026Article
- MiR-4701-3p predicts prognosis of non-small cell lung cancer and regulates cell biological behaviors.Hereditas · 2025Article
- QuantitativeEuropean journal of nuclear medicine and molecular imaging · 2025Article
- Approaches to Imaging Immune Activation Using PET.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Review
- [European journal of nuclear medicine and molecular imaging · 2025Article
- Navigating the landscape of neoadjuvant immunotherapy for NSCLC: progress and controversies.Therapeutic advances in medical oncology · 2025Review
- The utility ofCancer imaging : the official publication of the International Cancer Imaging Society · 2024Article
- Potential predictors of the pathologic response after neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer: a narrative review.Translational lung cancer research · 2024Review
- Comments on "dynamicThoracic cancer · 2022Article
- DynamicThoracic cancer · 2022Article
- ComprehensiveFrontiers in immunology · 2022Article
Corrections and comments
- Commented on by
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Major pathological response (MPR) is a potential surrogate for overall survival. We determined whether the dynamic changes in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.